| 1. |
Scagliotti G, Novello S, von Pawel J, et al. PhaseⅢ study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(11): 1835-1842.
|
| 2. |
Mcdermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phaseⅡ study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group[J]. J Clin Oncol, 2008, 26(13): 2178-2185.
|
| 3. |
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 501-513.
|
| 4. |
Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phaseⅢ study[J]. J Clin Oncol, 2012, 30(9): 921-929.
|
| 5. |
Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phaseⅢ, randomized, open-label trial[J]. Clin Breast Cancer, 2011, 11(2): 82-92.
|
| 6. |
Barrios CH, Liu MC, Lee SC, et al. PhaseⅢ randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer[J]. Breast Cancer Res Treat, 2010, 121(1): 121-131.
|
| 7. |
Grávalos C, Grande E, Gasent JM. The potential role of sunitinib in gastrointestinal cancers other than GIST[J]. Crit Rev Oncol Hematol, 2010, 76(1): 36-43.
|
| 8. |
Govidan V, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phaseⅢ trial[J]. J Clin Oncol, 2012, 30(17): 2070-2078.
|
| 9. |
Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction[J]. Blood, 2006, 107(11): 4532-4539.
|
| 10. |
Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model[J]. Cancer Res, 2008, 68(9): 3323-3333.
|
| 11. |
Montemurro M, Schöffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib[J]. Eur J Cancer, 2009, 45(13): 2293-2297.
|
| 12. |
陶玲, 卓文磊, 楊帆, 等. 凡德他尼治療非小細胞肺癌的meta分析[J]. 中國肺癌雜志, 2012, 5( 03): 172-178.
|
| 13. |
Lin NU, Diéras V, Paul D, et al. Multicenter phaseⅡ study of lapatinib in patients with brain metastases from HER2-positive breast cancer[J]. Clin Cancer Res, 2009, 15(4): 1452-1459.
|
| 14. |
Kim HP, Han SW, Kim SH, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells[J]. Mol Cancer Ther, 2008, 7(3): 607-615.
|
| 15. |
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2012, 379(9829): 1879-1886.
|
| 16. |
Rugo HS, Herbst RS, Liu G, et al. PhaseⅠ trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results[J]. J Clin Oncol, 2005, 23(24): 5474-5483.
|
| 17. |
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial[J]. Lancet, 2011, 378(9807): 1931-1939.
|
| 18. |
Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms[J]. Blood, 2010, 115(15): 3109-3117.
|
| 19. |
Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. N Engl J Med, 2012, 366(9): 799-807.
|
